The therapeutic and prognostic role of cuproptosis-related genes in triple negative breast cancer

BMC Bioinformatics

Table 1 The risks of CRGs in the cox proportional hazard model of TNBC

Features	Coef	HR	HR 95% CI		p value	Significance
Purity	4.262	70.973	8.718	5.778090e+02	0.000	*** (p ≤ 0.001)
Stage2	11.221	74,712.949	25,590.291	2.181306e+05	0.000	***
Stage3	14.346	1,699,753.178	592,717.2	4.874434e+06	0.000	***
Stage4	17.631	45,386,564.737	4,067,480.4	5.064413e+08	0.000	***
Age	0.022	1.023	0.984	1.062000	0.250
NFE2L2	− 1.823	0.162	0.073	0.358	0.000	***
NLRP3	2.379	10.797	5.438	21.437	0.000	***
ATP7B	1.547	4.698	2.236	9.871	0.000	***
ATP7A	− 1.142	0.319	0.151	0.673	0.003	** (0.05 < p < 0.001)
SLC31A1	− 1.185	0.306	0.141	0.662	0.003	**
FDX1	0.318	1.374	0.622	3.037	0.432
LIAS	0.787	2.197	0.941	5.125	0.069	·
LIPT1	0.402	1.495	0.499	4.486	0.473
LIPT2	0.923	2.516	0.886	7.144	0.083	·
DLD	0.234	1.264	0.634	2.52	0.506
DLAT	− 1.180	0.307	0.164	0.577	0.000	***
PDHA1	0.144	1.155	0.513	2.602	0.728
PDHB	1.533	4.630	1.285	1.669	0.019	* (p ≤ 0.05)
MTF1	0.273	1.313	0.581	2.97	0.512
GLS	0.530	1.699	1.067	2.705	0.026	*
CDKN2A	− 0.045	0.956	0.772	1.182	0.676
DBT	0.596	1.815	0.578	5.695	0.307
GCSH	− 0.516	0.597	0.310	1.148	0.122
DLST	2.625	13.804	4.360	43.704	0.000	***

*, **, *** respectively represent p values less than or equal to 0.05, p values between 0.05 and 0.001, and p values less than or equal to 0.001 after two-tailed T-test calculation

ISSN: 1471-2105